Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : NS-050/NCNP-03
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Grants Rare Pediatric Disease Designation For NS-050/NCNP-03 in DMD
Details : NS-050/NCNP-03 is an antisense oligonucleotide and is being developed for the treatment of Duchenne muscular dystrophy (Duchenne).
Brand Name : NS-050/NCNP-03
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 10, 2024
Lead Product(s) : NS-050/NCNP-03
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Viltolarsen
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
NS Pharma Shares Preliminary Results Of Viltolarsen Phase 3 Trial
Details : Viltepso (viltolarsen), an antisense oligonucleotide, is being investigated in ambulatory boys with Duchenne muscular dystrophy.
Brand Name : Viltepso
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 27, 2024
Lead Product(s) : Viltolarsen
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : NS-229
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
EC Grants Orphan Drug Designation to NS-229 for Eosinophilic Granulomatosis
Details : NS-229 is a potent and selective Janus kinase (JAK) 1 inhibitor. It is being evaluated in phase 2 clinical trials for the treatment of eosinophilic granulomatosis with polyangiitis.
Brand Name : NS-229
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 22, 2024
Lead Product(s) : NS-229
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Brogidirsen
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : NS-089/NCNP-02 (brogidirsen) targets a gene mutation that can be treated by exon 44 skipping. It is being evaluated in phase 2 clinical trials for the treatment of Duchenne Muscular Dystrophy.
Brand Name : NS-089/NCNP-2
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 21, 2023
Lead Product(s) : Brogidirsen
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ilginatinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : NS-018 (ilginatinib), is a highly selective and potent inhibitor of JAK2. It is being investigated for the treatment for myelofibrosis (MF), a rare and incurable blood cancer.
Brand Name : NS-018
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 08, 2023
Lead Product(s) : Ilginatinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Brogidirsen
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : NS-089 (brogidirsen) which is a novel phosphorodiamidate morpholino oligomer that consists of a novel sequence design involving connected antisense oligonucleotides, targeting exon 44, to serve as an effective treatment for DMD patients amenable to exon ...
Brand Name : NS-089
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 07, 2023
Lead Product(s) : Brogidirsen
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Brogidirsen
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : NS-089/NCNP-02 (brogidirsen) which is a novel phosphorodiamidate morpholino oligomer that consists of a novel sequence design involving connected antisense oligonucleotides, targeting exon 44, to serve as an effective treatment for DMD patients amenable ...
Brand Name : NS-089
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 07, 2023
Lead Product(s) : Brogidirsen
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : NS-050/NCNP-03
Therapeutic Area : Genetic Disease
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : NS-050/NCNP-03, an investigational candidate for patients with Duchenne muscular dystrophy amenable to exon 50 skipping therapy. Study assessments will include dystrophin production, muscle strength, mobility and functional exercise capacity.
Brand Name : NS-050/NCNP-03
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
June 15, 2023
Lead Product(s) : NS-050/NCNP-03
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : NCNP-02
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : NS-089/NCNP-02 which is a novel phosphorodiamidate morpholino oligomer that consists of a novel sequence design involving connected antisense oligonucleotides, targeting exon 44, to serve as an effective treatment for DMD patients amenable to exon 44 ski...
Brand Name : NS-089
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 14, 2023
Lead Product(s) : NCNP-02
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ilginatinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : NS-018 (ilginatinib), is a highly selective and potent inhibitor of JAK2. It is being investigated for the treatment for myelofibrosis (MF), a rare and incurable blood cancer.
Brand Name : NS-018
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 17, 2023
Lead Product(s) : Ilginatinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?